EDP-239(EDP-239) - 药物靶点：Hepatitis C virus NS 5 protein_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

Hepatitis C virus NS 5 protein

作用机制

丙型肝炎病毒NS 5蛋白抑制剂

治疗领域

感染消化系统疾病

在研适应症-

非在研适应症

慢性丙型肝炎

原研机构

Enanta Pharmaceuticals, Inc.

在研机构-

非在研机构

Enanta Pharmaceuticals, Inc.

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C44H52N8O6

InChIKeyLBWDUXHLFJNSJJ-ZYADHFCISA-N

CAS号1242088-65-8

关联

2

项与 EDP-239 相关的临床试验

NCT02173574 / Completed临床1期

An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects

The purpose of Part 1 is to inform dose selection for use of alisporivir and EDP239 in combination and obtain initial safety data for co-administration of alisporivir and EDP239 to support future treatment studies in patients. The purpose of Part 2 is to inform the drug-drug interaction potential of EDP239 more broadly and possibly facilitate the interpretation of lower than expected alisporivir concentrations in Part 1, if observed.

开始日期2014-08-01

申办/合作机构

Enanta Pharmaceuticals, Inc.

NCT01856426 / Completed临床1期

Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects

The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.

开始日期2013-06-01

申办/合作机构

Enanta Pharmaceuticals, Inc.

100 项与 EDP-239 相关的临床结果

登录后查看更多信息

100 项与 EDP-239 相关的转化医学

登录后查看更多信息

100 项与 EDP-239 相关的专利（医药）

登录后查看更多信息

100 项与 EDP-239 相关的药物交易

登录后查看更多信息